The intestinal microbiome as a predictive biomarker for efficacy and side effects of CAR-T cell therapy in blood cancers

The intestinal microbiome as a predictive biomarker for efficacy and side effects of CAR-T cell therapy in blood cancers - MiCART

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00020506

Enrollment

Registered

2020-01-20

Start date

2020-01-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C91.0 C83.3

Interventions

Group 1: Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and patients with relapsed or refractory acute lymphocytic leukemia (ALL) who have been selected for treatment with

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: -lymphoma / leukemia patients with medically indicated CD19 CAR-T cell therapy -persons who have understood the informed consent and signed the written consent form

Exclusion criteria

Exclusion criteria: - Refusal by the patient - Lack of ability to consent

Design outcomes

Primary

Measure	Time frame
The main outcome is bacterial alpha diversity according to Simpson (AD) at the time of CAR-T cell therapy, which should be associated with survival within 24 months.	—

Secondary

Measure	Time frame
Remission, Relapse, Therapy-associated toxicity [CRS, ICANS]	—

Countries

Germany

Contacts

Public ContactChristoph Stein-Thoeringer

German Cancer Research Center (DKFZ)

c.stein-thoeringer@dkfz-heidelberg.de+496221424952

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026